PREAMBLE
The American College of Cardiology (ACC)/American Heart Association (AHA) performance measure sets serve as vehicles to accelerate translation of scientific evidence into clinical practice. Measure sets developed by the ACC/AHA are intended to provide practitioners and institutions that deliver cardiovascular services with tools to measure the quality of care provided and identify opportunities for improvement.
Writing committees are instructed to consider the methodology of performance measure development (1) and to ensure that the measures developed are aligned with ACC/AHA clinical practice guidelines. The writing committees also are charged with constructing measures that maximally capture important aspects of care quality, including timeliness, safety, effectiveness, efficiency, equity, and patient-centeredness, while minimizing, when possible, the reporting burden imposed on hospitals, practices, and/or practitioners. All the measures included in the measure set are briefly summarized in Table 1 , which provides information on the measure number, title, care setting, attribution, and domain. The detailed measure specifications (available in Appendix A) provide not only the information included in Table 1 , but also more detailed information including the measure description, numerator, denominator (including denominator exclusions and exceptions), rationale for the measure, guideline recommendations that support the measure, measurement period, and sources of data.
The writing committee has developed a comprehensive STEMI/NSTEMI measure set that includes 24 total measures of which 17 are performance measures and 7 are quality measures (as reflected in Table 1 and Appendix A).
The writing committee believes that implementation of this measure set by healthcare providers, physician practices, and hospital systems will enhance the quality of care and likely improve outcomes of patients with STEMI and NSTEMI.
Scope of the Problem
Acute myocardial infarction (AMI) is a frequent cause of hospital admission in the United States and is associated with significant short-and long-term mortality and morbidity. Every 42 seconds, approximately 1 American will suffer an AMI, and the estimated annual incidences of new and recurrent MI events are 550,000 and 200,000 events, respectively (3) .
Fortunately, the rates of hospitalization and 30-day mortality for AMI have been on the decline (4, 5) . This reduction in mortality is likely related to the shift in the pattern of clinical presentation of AMI as well as to improved acute treatments and long-term care. Yeh and colleagues examined age-and sex-adjusted incidence rates for STEMI and NSTEMI from a community-based population (Northern California) between 1999 and 2008 , and demonstrated an overall significant decrease in AMI incidence rate after 2000 (6) . Although the adjusted 30-day mortality rate after AMI decreased significantly (driven by a significant reduction in NSTEMI mortality), the overall mortality rate in 2008 after an AMI was still 7.8% at 30 days (6) .
Importantly, AMI patients who survive the initial event have substantial risk for future cardiovascular events, including recurrent MI, death, heart failure, and stroke. In the PLATO (Platelet Inhibition and Patient Outcomes) trial, the rate of the combined cardiovascular endpoint (vascular death, MI, or stroke) was 11.7% at 12 months among AMI patients treated with aspirin and clopidogrel (7) . This included a 6.9% rate of recurrent MI at 12 months (7) . In 2010 alone, about 595,000 inpatient hospital discharges were attributed to AMI (3) . AMI is also associated with a substantial direct and indirect cost burden, and is classified among the top 10 most expensive hospital principal discharge diagnoses (3) .
As indicated in the Third Universal Definition of
Myocardial Infarction consensus document published in 2012 (8) , AMI is defined by the detection of a rise and/or fall of cardiac biomarkers (preferably cardiac troponin levels) with at least 1 value above the 99th percentile upper reference limit and with at least one of the following: (a) symptoms of ischemia; (b) The measure set developed by our writing committee applies only to MI type 1 and does not uniformly apply to the other 4 types of MI. In fact, some of those measures are even contraindicated with certain MI type, such as aspirin or P2Y 12 receptor inhibitor therapies, which are contraindicated in patients with a MI type 2 resulting from severe hemorrhage and anemia. Given the widespread use of very sensitive assays for markers of myocardial necrosis (e.g., the highly sensitive and specific cardiac troponin [cTn] biomarkers) and advanced imaging modalities, very small amounts of myonecrosis unrelated to ischemia can be detected (e.g., heart failure, renal failure, myocarditis, pulmonary embolism). Our measures also do not apply to these myocardial injury events, which should be differentiated from true AMI events.
For the sake of immediate treatment strategies (e.g., reperfusion therapy), AMI is differentiated into STEMI and NSTEMI, depending on the existence of ST-segment elevation in $2 contiguous leads on the presenting ECG.
Acute STEMI equivalent can, however, manifest as:
hyperacute T-wave changes, true posterior MI, multilead ST depression with coexistent ST elevation in lead aVR, characteristic diagnostic criteria in the setting of left bundle branch block. The proportion of STEMI versus NSTEMI events varies in different registries and depends on the age of patients, their geographic location, and the type of surveillance used. In general, STEMI patients account for 29% to 47% of all AMI patients (9, 10) .
Updating the existing STEMI/NSTEMI measure set was a priority for the ACC and AHA. Particular attention was given to evidence-based diagnostic and therapeutic stra- 
METHODOLOGY

Literature Review
In developing the updated STEMI/NSTEMI measure set, the writing committee reviewed evidence-based guidelines and statements that would potentially impact the construct of the measures. The practice guidelines and statements that most directly contributed to the development of these measures are summarized in Table 2 .
Definition and Selection of Measures
The writing committee reviewed recent clinical practice guidelines and other clinical guidance documents ( he/she will not take the medication due to a number of reasons (e.g., concerns about its bleeding risk). In this case, the provider would receive credit for the measure. However, if the patient had explicitly expressed to the provider that he/she did not wish to have the medication prescribed, no prescription will be written and the provider can then document in the medical record patient's refusal of the medication. In this scenario, the provider will not be penalized for this performance measure because a valid patient reason is documented. The writing committee closely deliberated the exceptions to be included with each measure and, in some cases, determined not to include any exceptions (as in the case of the patient safety measures).
During the course of developing the measure set, the writing committee evaluated the potential measures against the ACC/AHA attributes of performance measures (Table 3) to reach consensus on which measures should be advanced for inclusion in the final measure set. After the peer review and public comment period, the writing committee reviewed and discussed the comments received, and further refined the measure set. The writing committee acknowledges that the new measures created in this set will need to be tested and validated over time.
By publishing this performance and quality measure set, the writing committee hopes to encourage their widespread and expeditious adoption, as well as facilitate the collection and analysis of data that are needed to continuously assess their relevance over time. In the future, the writing committee members anticipate having data that will allow them to reassess whether any of the measures included in this set should be revised (e.g., modified, deleted, or potentially upgraded from a quality measure to a performance measure).
AHA/ACC STEMI AND NSTEMI MEASURE SET PERFORMANCE MEASURES
Discussion of Changes to 2008 STEMI and NSTEMI
Measure Set
After reviewing the existing guidelines, and the 2008 performance and quality measure set (2), the writing committee discussed which measures should be revised to reflect the updated science, and worked to identify which guideline recommendations could serve as the basis for new performance or quality measures. The writing committee also reviewed existing measure sets that were publicly available.
The following subsections serve as a synopsis of the revisions that were made to previous measures, and a description of why the new inpatient measures were created.
Retired Measures
The writing committee decided to retire 1 performance measure for smoking cessation counseling because of the consistently high levels of performance achieved (Table 4) . Other quality measures, previously included as test measures in the 2008 measure set, were retired for the reasons specified in Table 4 .
Revised Measures
The writing committee reviewed and made changes to 4 measures, which are summarized in Table 5 . Most the changes were made to reflect the new evidence and updated guideline recommendations, to strengthen the measure construct, or to expand the measures to include new proven pharmacotherapies.
New Measures
The new measure set includes 4 performance measures and 7 quality measures. Table 6 includes a list of the new measures and their rationale.
Four of the quality measures are structured in a typical format in which the goal is to seek a score of 100%.
However, 3 of the new quality measures are safety measures and, in those, the goal is to seek a score of 0% (e.g., 0% use or prescription of an inappropriate treatment reflects an optimal quality of care).
For more detailed information on the measure construct, please refer to the detailed measure specifications summarized in Appendix A.
TA BLE 3 ACC/AHA Task Force on Performance Measures: Attributes for Performance Measures (26)
Evidence Based
High-impact area that is useful in improving patient outcomes a) For structural measures, the structure should be closely linked to a meaningful process of care that in turn is linked to a meaningful patient outcome. b) For process measures, the scientific basis for the measure should be well established, and the process should be closely linked to a meaningful patient outcome. c) For outcome measures, the outcome should be clinically meaningful. If appropriate, performance measures based on outcomes should adjust for relevant clinical characteristics through the use of appropriate methodology and high-quality data sources.
Measure Selection
Measure definition a) The patient group to whom the measure applies (denominator) and the patient group for whom conformance is achieved (numerator) are clearly defined and clinically meaningful.
Measure exceptions and exclusions b) Exceptions and exclusions are supported by evidence.
Reliability c)
The measure is reproducible across organizations and delivery settings.
Face validity d) The measure appears to assess what it is intended to.
Content validity e) The measure captures most meaningful aspects of care.
Construct validity f) The measure correlates well with other measures of the same aspect of care.
Measure Feasibility
Reasonable effort and cost a) The data required for the measure can be obtained with reasonable effort and cost.
Reasonable time period b) The data required for the measure can be obtained within the period allowed for data collection.
Accountability
Actionable a) Those held accountable can affect the care process or outcome.
Unintended consequences avoided b) The likelihood of negative unintended consequences with the measure is low.
ACC indicates American College of Cardiology; AHA, American Heart Association.
TA BLE 5
Revised The writing committee felt it is best to keep this as a quality measure because of issues related to the measure construct. This measure is likely to present a significant abstraction burden and may be relevant only to a small fraction of AMI patients (given the elaborate inclusion/exclusion criteria in the EPHESUS (29) clinical trial).
AREAS FOR FURTHER RESEARCH
The writing committee recognizes that the ultimate measure of performance lies in the assessment of outcomes, such as mortality (in-hospital or 30-day), health status, and other outcomes (recurrent MI, urgent repeat revascularization). However, the complexity associated with adjustment for the large number of patient characteristics that both influence treatment decisions and impact mortality make these measures less attractive to use. Thirty-day risk-adjusted AMI mortality has been used by CMS for payment incentives and in public reporting.
The impact of these and other measures on hospital quality should be the focus of future research. The committee also realizes that many measures are already (11) guidelines, cautioning against the use of prasugrel in patients with prior TIA/stroke, because of net clinical harm in these patients. The FDA also issued a black box warning on this.
The writing committee felt it is best to keep this as a quality measure only for the time being until more data become available pertinent to this measure and its impact in real-world patients. (11) guidelines, cautioning against the use of high-dose aspirin >100 mg among patients receiving ticagrelor. The FDA also issued a black box warning on this.
The writing committee felt it is best to keep this as a quality measure only for the time being until more data become available pertinent to this measure and its impact in real-world patients. 
Care Setting Inpatient
Rationale
Coronary heart disease with atherosclerotic plaque disruption (e.g., rupture, erosion, ulceration) and superimposed platelet-rich thrombus formation are the main pathophysiological mechanisms causing MI (type 1 or spontaneous MI). Acute occlusion of the coronary artery by the "plaque þ superimposed thrombus complex" results in acute imbalance in myocardial oxygen demand and supply which, when prolonged and unabated, leads to myocardial cell necrosis and infarction. Acute and complete occlusion of the coronary artery usually results in STEMI, which usually presents with persistent ST-elevation on the ECG or as an STEMI equivalent (hyperacute T-wave changes, true posterior MI, multilead ST depression with coexistent ST-elevation in lead aVR, characteristic diagnostic criteria in the setting of LBBB). On the other hand, severely obstructive but incompletely occlusive coronary lesions usually result in NSTEMI, characterized by the absence of persistent ST elevation on ECG, but rather the presence of ST depression, T-wave inversion or other nonspecific changes. Aspirin inhibits the formation of thromboxane A2, a potent stimulator of platelet aggregation, and is the first-line therapy for AMI (30). A loading dose of 162 to 325 mg of non-enteric-coated aspirin formulation should be administered as soon as possible (to be crushed or chewed to achieve rapid absorption), followed preferably by an 81-mg daily dose to minimize bleeding risk. (30-34) In the ISIS-2 (Second International Study of Infarct Survival) trial (30), aspirin therapy administered within the first 24 h after acute STEMI resulted in a 23% relative risk reduction in 5-week vascular mortality (or 2.4% absolute risk reduction) in patients with STEMI. Significant reductions in the incidence of non-fatal reinfarction and stroke were also observed with aspirin (30). (11) 1. Non-enteric-coated, chewable aspirin (162 mg to 325 mg) should be given to all patients with NSTE-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 mg/d to 162 mg/d) should be continued indefinitely (7, (39) (40) (41) (42) . (Class I, Level of Evidence: A) 2. Patients not on aspirin therapy should be given nonÀenteric-coated aspirin (325 mg) as soon as possible before PCI (35, 36, 43, 44) . (Class I, Level of Evidence: B) 3. In patients with NSTE-ACS who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered (45). 
Clinical Recommendation(s)
2013
APPENDIX A. STEMI AND NSTEMI PERFORMANCE MEASURES
Performance Measures for Use in Patients With Inpatient STEMI and NSTEMI
Inpatient Measures
Jneid et al. Denominator Exceptions Documentation of a medical reason for not prescribing aspirin at discharge (e.g., aspirin allergy or intolerance, oral anticoagulant therapy at discharge, active bleeding) Patient currently enrolled in a clinical trial precluding the use of aspirin in its protocol (e.g., trials of triple versus dual therapy in atrial fibrillation patients)
Measurement Period Encounter
Sources of Data
Medical record or other database (e.g., administrative, clinical, registry)
Attribution Measure reportable at the facility or provider level
Care Setting Inpatient
Rationale
Coronary heart disease with atherosclerotic plaque disruption (e.g., rupture, erosion, ulceration) and superimposed platelet-rich thrombus formation are the main pathophysiological mechanisms causing MI (type 1 or spontaneous MI). Acute occlusion of the coronary artery by the "plaque þ superimposed thrombus complex" results in acute imbalance in myocardial oxygen demand and supply which, when prolonged and unabated, leads to myocardial cell necrosis and infarction. Aspirin inhibits the formation of thromboxane A2, a potent stimulator of platelet aggregation, and is the first-line therapy for AMI (30). Following an initial loading dose of 162 to 325 mg of non-enteric-coated aspirin, an 81-mg daily dose is preferred to higher doses to minimize bleeding risk (31-34). Aspirin should be continued indefinitely after a MI (46). The Antithrombotic Trialists' Collaboration's meta-analyses firmly confirmed the benefits of long-term aspirin therapy in patients at high-risk of occlusive vascular events, including patients with prior or acute MI (32). A subsequent meta-analysis inclusive of 16 secondary prevention trials (n¼17,000 patients) compared long-term aspirin versus control and demonstrated that aspirin allocation was associated with a 1.5% significantly lower risk of serious vascular events per year, as well as significant reductions in coronary events and total stroke events (39). Denominator Exceptions Documentation of a medical reason for not prescribing a beta blocker at hospital discharge (e.g., beta-blocker allergy or intolerance, advanced heart block and no pacemaker, significant bradycardia or hypotension prior to discharge, active asthma or reactive airways disease, increased risk of heart failure/cardiogenic shock, recent history of cocaine or methamphetamine use with signs of acute intoxication)
Clinical Recommendation(s)
Measurement Period Encounter
Sources of Data
Care Setting Inpatient
Rationale
Beta blockers are excellent anti-ischemic and antianginal medications that decrease myocardial oxygen demand by reducing the heart rate, blood pressure, and contractility. They also reduce cardiac automaticity and the risk of VF after MI. In addition, they improve coronary perfusion by prolonging diastole. Oral beta blockers should therefore be administered to all patients with MI without contraindications for their use. Common contraindications for beta blockers use include heart failure or risk for cardiogenic shock, bradycardia, hypotension, heart block, or active bronchospasm, or acute cocaine ingestion. Patients with initial contraindications to beta blockers in the first 24 h after an AMI should be reevaluated to determine their subsequent eligibility. A systematic review of randomized controlled trials inclusive of 54,234 patients with acute or prior MI demonstrated that beta blockers are effective in secondary prevention after MI and impart a 23% reduction in the odds of death in long-term trials (48). Notably, the evidence is established predominantly in the prereperfusion era among patients with STEMI. The effects of beta blockers appear also to be greatest among patients with MI complicated by heart failure, systolic cardiomyopathy, or ventricular arrhythmias (48). Although not prospectively studied, the AHA/ACCF secondary prevention guidelines recommend a 3-year treatment course with beta blockers for patients with uncomplicated MI (13). Many of these patients, however, have either hypertension or heart failure/systolic cardiomyopathy, and are usually continued on an oral beta blocker indefinitely. It is advisable to use beta blockers without intrinsic sympathomimetic activity, and in patients with MI complicated with systolic cardiomyopathy with or without heart failure, 1 of the 3 proven beta blockers should be used: carvedilol, sustained-release metoprolol succinate, or bisoprolol. Measure Description: Percentage of patients age $18 y, hospitalized with AMI, who were prescribed a high-intensity statin at hospital discharge.
Clinical Recommendation(s)
Numerator
Patients with AMI who are prescribed a high-intensity statin* at hospital discharge *High-intensity statin dose is defined in Denominator Exceptions Documentation of a medical reason for not prescribing a high-intensity statin (e.g., allergy, intolerance or contraindications to high-intensity statin(s), risk of interaction between drugs, or other medical reasons) Documentation of prescription of a moderate-intensity statin for patients >75 y of age Documentation of a patient reason for not prescribing a statin (e.g., patient refusal) Patient currently enrolled in a clinical trial related to lipid-lowering therapy
Measurement Period Encounter
Sources of Data
Care Setting Inpatient
Rationale
Patients with an MI are at high risk for recurrent cardiovascular events. Statins inhibit the HMG-CoA reductase enzyme, the rate-limiting step in cholesterol biosynthesis, and are powerful drugs for lowering LDL-C, with reductions $50% observed with the high-intensity statin regimens. Statins have been shown in multiple secondary prevention trials to reduce cardiovascular events, including coronary heart disease death, recurrent MI, cerebrovascular events, coronary revascularization, and all-cause mortality (50-52). They have also been shown to delay coronary atherosclerosis progression and possibly induce plaque regression, on serial angiographic and intravascular ultrasonographic studies. Given that the clinical evidence does not support the notion of titrating statin therapy to achieve a proposed LDL-C target and that statins are beneficial in all patients at high cardiovascular risk irrespective of their LDL-C levels, the paradigm of treating patients to LDL-C targets is largely abandoned (14,18). On the other hand, highintensity statin therapy appears to confer incremental clinical benefit compared with less intensive therapy (53). The Cholesterol Treatment Trialists conducted meta-analyses of individual participant data from randomized trials of more versus less intensive statin regimens (5 trials; 39,612 patients) (53). They demonstrated that more intensive regimens produced a highly significant 15% further reduction in major vascular events, driven by reductions in coronary death or non-fatal MI, coronary revascularization, and ischemic stroke (53). The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommends treatment of patients #75 y of age who have clinical atherosclerotic cardiovascular disease (including those with MI) with high-intensity statin (14). Moderate-intensity statins are recommended in their counterparts >75 y of age and in those who have contraindications/intolerance to high-intensity regimens. The guideline emphasizes that statin therapy should be individualized in persons >75 y of age according to the potential for ASCVD risk-reduction benefits, adverse effects, drug-drug interactions, and patient preferences (14). Improved compliance with therapy is an impetus for timing the initiation of statin therapy before discharge in patients hospitalized with acute MI.
Clinical Recommendation(s)
The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (14): 1. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men #75 years of age who have clinical ASCVD, unless contraindicated. (Class I, Level of Evidence: A) 2. In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated † or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin therapy should be used as the second option if tolerated. (Class I, Level of Evidence: A) 3. In individuals with clinical ASCVD* >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate-or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it. (Class IIA; Level of Evidence: B)
*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin. †Contraindications, warnings, and precautions are defined for each statin according to the manufacturer's prescribing information (14).
ACC indicates American College of Cardiology; ASCVD, atherosclerotic cardiovascular disease; AHA, American Heart Association; AMI, acute myocardial infarction; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; LDL-C, low-density lipoprotein-cholesterol; MI, myocardial infarction; and TIA, transient ischemic attack.
APPENDIX A. CONTINUED
SHORT TITLE: PM-5
Evaluation of LVEF PM-5: AMI: Evaluation of LVEF Measure Description: Percentage of patients, age $18 y, hospitalized with AMI, with documentation in the hospital record that LVEF is evaluated during hospitalization or is planned for after discharge.
Numerator
Patients with AMI with documentation in the hospital record that LVEF assessment, which can be either qualitative or quantitative, is done during the hospitalization or is planned for after discharge Denominator All patients with AMI
Denominator Exclusions
Patients age <18 y Patients who leave against medical advice Patients who die during hospitalization Patients who are on comfort care measures only or hospice Patients who are transferred to another hospital for inpatient acute care
Denominator Exceptions None
Measurement Period Encounter
Sources of Data
Care Setting Inpatient
Rationale LVEF is important from a therapeutic and prognostic standpoint for patients with acute AMI for many reasons: Patients with reduced LVEF may benefit from specific medical therapies, such as inhibitors of the renin-angiotensin-aldosterone system. The presence of LVSD may help inform and guide the invasive strategy and revascularization modality (e.g., further risk stratification in patients with NSTEMI, use of percutaneous circulatory assist devices during percutaneous coronary interventions, choice of surgical revascularization). LVEF is one of the strongest predictors of long-term survival following AMI. LVEF measurement during hospitalization provides a baseline and dictates outpatient reassessment a few weeks later in patients with initially depressed post-MI LVEF. This will help guide the need for device therapy. LV function can be assessed by a variety of modalities (e.g., contrast ventriculography, echocardiography, CT angiography). However, a transthoracic echocardiogram is most useful. It is noninvasive, relatively inexpensive, and helps provide a comprehensive assessment of the LV function (regional and global) and size, and rule out post-MI mechanical and other complications. 
APPENDIX A. CONTINUED
Jneid et al. Measure Description: Percentage of patients, age $18 y, hospitalized with AMI and LVSD who are prescribed an ACEI or ARB at hospital discharge.
Numerator
Patients with AMI with LVSD (defined as chart documentation of a LVEF <40% or a narrative description of LVSF consistent with moderate or severe systolic dysfunction) who are prescribed an ACEI or ARB* at hospital discharge *Fixed dose combination medications that contain ACEI or ARB therapy fulfill the numerator criteria if prescribed (e.g., the ARNI, sacubitril/valsartan, contains the ARB valsartan and would fulfill the measure criteria if prescribed).
Denominator
All AMI patients with LVSD
Denominator Exclusions
Patients age <18 y Patients who leave against medical advice Patients who die during hospitalization Patients who are on comfort care measures only or hospice Patients who are transferred to another hospital for inpatient care
Denominator Exceptions Documentation of medical reasons for not prescribing an ACEI and not prescribing an ARB at discharge (e.g., allergy or intolerance to ACEI and ARB including: angioedema, hyperkalemia, hypotension, renal artery stenosis, worsening renal function)
Measurement Period Encounter
Sources of Data
Care Setting Inpatient
Rationale
ACEIs improve survival in patients with AMI, particularly in those with reduced LVEF. They attenuate LV remodeling and infarct expansion and have a variety of additional beneficial effects (effects on ischemic preconditioning, fibrinolysis, recurrent MI, sudden death). The SAVE (Survival and Ventricular Enlargement) trial demonstrated the benefits of captopril in reducing mortality, recurrent MI and HF hospitalization in AMI patients with an LVEF <40%, but without overt HF on entry (59). Other studies showed comparable findings (60,61). ARBs are reasonable alternatives to ACEIs in patients with AMI and LVSD and can be used for patients who are intolerant to ACEIs. In the VALIANT (Valsartan in Acute Myocardial Infarction) trial, losartan was noninferior to captopril in patients with MI complicated by LVSD, HF, or both (62). Common contraindications to the use of these agents include hypotension, shock, bilateral renal artery stenosis, worsening of renal function with ACEI/ARB exposure, and drug allergy. The ARNI, valsartan/sacubitril, is the first approved ARNI for the treatment of patients with HF and reduced ejection fraction. Compared with the ACEI, enalapril, it reduced the composite endpoint of cardiovascular death or HF hospitalization in the pivotal PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial (17). The ARNI is even recommended as a replacement therapy for symptomatic HF reduced ejection fraction with New York Heart Association class II or III who tolerate an ACEI or ARB (17). An ACEI should not be added to AMI patients already treated with an ARNI given the increased risk of angioedema and other complications (e.g., hypotension, renal insufficiency). Additionally, an ARB is already a component of the ARNI regimen and as such, adding ARB is not clinically advocated. 
Clinical Recommendation(s)
Denominator
All patients with acute STEMI and its equivalent
Denominator Exclusions
Patients age <18 y Patients received in transfer from the inpatient, outpatient, or ED of another facility
Denominator Exceptions Documentation of a medical reason for delayed fibrinolytic therapy (e.g., cardiopulmonary arrest, initial suspicion of bleeding/ stroke or other contraindications to use fibrinolytic therapy, respiratory failure requiring intubation, intra-aortic balloon pump insertion, late presentation >12 h after symptom onset) Documentation of a patient reason (e.g., initial patient concern with bleeding hazards)
Measurement Period Encounter
Sources of Data
Care Setting Inpatient
Rationale
In the ISIS-2 (Second International Study of Infarct Survival) trial (30), the fibrinolytic streptokinase significantly reduced 5-week vascular mortality by 2.8% compared to placebo, which remained significant at a median follow-up of 15 mo. In that trial, the combination of streptokinase and aspirin was also associated with significantly fewer reinfarction, stroke, and death events compared to placebo (30). The benefits of acute reperfusion with fibrinolytic therapy in patients with STEMI was further corroborated by the report from the Fibrinolytic Therapy Trialists, which included nine trials randomizing a total of 58,600 patients to fibrinolytic therapy versus control (70). The aforementioned collaborative report also demonstrated an inverse relation between the benefit from fibrinolytic therapy and delay from symptom onset, with highly significant absolute mortality reductions of 3% for patients presenting within 0 to 6 h and 2% for those presenting 7 to 12 h from symptom onset (70). The ACCF/AHA guideline for the management of STEMI (12) recommends that patients who present with STEMI to a non-PCI-capable hospital should receive timely fibrinolytic therapy, if interhospital timely transfer time for primary PCI is not feasible (to achieve mechanical reperfusion within #120 min of FMC). Despite the lack of strong supporting evidence, the clinical consensus is also to consider fibrinolytic administration in symptomatic STEMI patients presenting >12 h after symptom onset with STEMI when PCI is not feasible and when there is a large myocardium at jeopardy or hemodynamic instability (12). The survival benefit observed with fibrinolytic agents is greatest when they are administered within the first 2 h after the onset of STEMI symptoms (71-73). As the length of time between patient's presentation and the delivery of fibrinolytic therapy (DTN time) increases, the benefit from therapy decreases and progressive increase in infarct size and reduction in LVEF ensue. Thus, the benefit of fibrinolytic therapy is most effective when provided promptly, and the ACCF/AHA guideline set a benchmark time goal from hospital arrival to drug administration, or DTN time, to be #30 min (12).
Clinical Recommendation(s)
2013 ACCF/AHA Guideline for the Management of Patients With ST-Elevation Myocardial Infarction (12) 1. In the absence of contraindications, fibrinolytic therapy should be administered to patients with STEMI at non-PCI-capable hospitals when the anticipated FMC-to-device time at a PCI-capable hospital exceeds 120 minutes because of unavoidable delays (70, 74, 75) . (Class I, Level of Evidence: B) 2. When fibrinolytic therapy is indicated or chosen as the primary reperfusion strategy, it should be administered within 30 minutes of hospital arrival* (71, 73, (76) (77) (78) . (Class I, Level of Evidence: B) 3. In the absence of contraindications, fibrinolytic therapy should be given to patients with STEMI and onset of ischemic symptoms within the previous 12 hours when it is anticipated that primary PCI cannot be performed within 120 minutes of FMC (30, 70, (79) (80) (81) (82) (83) . (Class I, Level of Evidence: A) 4. Fibrinolytic therapy should not be administered to patients with ST depression except when a true posterior (inferobasal) MI is suspected or when associated with ST elevation in lead aVR (70, (84) (85) (86) (87) . (Class III, Level of Evidence: B) 5. In the absence of contraindications, fibrinolytic therapy should be administered to patients with STEMI and cardiogenic shock who are unsuitable candidates for either PCI or CABG (70, 88, 89 Attribution Measure reportable at the facility or provider level
Care Setting Inpatient
Rationale
Primary PCI has been shown to be superior to fibrinolytic therapy in recanalizing the infarct-related artery and imparts better clinical outcomes (90, 91) . In a metaanalysis of 23 trials randomizing a total of 7,739 patients with acute STEMI to primary angioplasty or fibrinolytic therapy, primary angioplasty was superior in reducing short-term mortality, nonfatal reinfarction, stroke, and the combined cardiovascular endpoint (92). Primary angioplasty also resulted in higher rates of infarct artery patency, TIMI flow, lower rates of recurrent ischemia, emergency repeat revascularization procedures, and intracranial hemorrhage (92). The benefits of primary angioplasty persisted during long-term follow-up and were independent of the type of fibrinolytic therapy used (92). 
Denominator
All patients with acute STEMI, or its equivalent, who are seen initially at a non-PCI-capable hospital and who are transferred to a PCI-capable hospital
Denominator Exclusions
Patients age <18 y Patients who are transferred for a PCI that is described as nonprimary treatment for AMI by a healthcare provider (e.g., patients who receive fibrinolytic therapy as the primary reperfusion therapy)
Denominator Exceptions Documentation of a medical reason for the delay (e.g., cardiopulmonary arrest, balloon pump insertion, respiratory failure requiring intubation) Documentation of a patient reason for the delay (e.g., initial concern, patient choice) Patient currently enrolled in a clinical trial related to AMI and reperfusion therapy Numerator AMI patients who are referred to outpatient CR/secondary prevention program prior to hospital discharge Denominator Number of hospitalized patients in the reporting period hospitalized with qualifying event/diagnosis
Measurement Period Encounter
Sources of Data
Denominator Exclusions None
Denominator Exceptions Provider-oriented criteria (patient deemed to have a high-risk condition or a contraindication to exercise, for example) Healthcare system barriers (e.g., financial barriers or lack of CR programs near a patient's home)
Measurement Period Encounter
Sources of Data
Care Setting Inpatient
Rationale
A key component to outpatient CR program utilization is the appropriate and timely referral of patients. Generally, the most important time for this referral to take place is while the patient is hospitalized for a qualifying event/diagnosis (e.g., MI, chronic stable angina, CABG, PCI, cardiac valve surgery, or cardiac transplantation). This performance measure has been developed to help healthcare systems implement effective steps in their systems of care that will optimize the appropriate referral of a patient to an outpatient CR program. This measure is designed to serve as a stand-alone measure or, preferably, to be included within other performance measurement sets that involve disease states or other conditions for which CR services have been found to be appropriate and beneficial (e.g., following MI, CABG surgery). This performance measure is provided in a format that is meant to allow easy and flexible inclusion into such performance measurement sets. Effective referral of appropriate inpatients to an outpatient CR program is the responsibility of the healthcare team within a healthcare system that is primarily responsible for providing cardiovascular care to the patient during the hospitalization. 
Care Setting Inpatient
Rationale
Some patients with AMI who are managed conservatively (e.g., managed with medical therapies, with coronary angiography not planned as an initial treatment strategy) have high-risk coronary artery disease. These patients may not experience spontaneous ischemia during their hospitalization and need to be further risk stratified before discharge with a stress test (preferably, a submaximal stress test). This will help identify the high-risk patient who needs invasive angiography and possible revascularization, predominantly to mitigate recurrent ischemia/MI (11, 12, (138) (139) (140) (141) . A noninvasive stress test can be exercise-based or pharmacological, and the means for detecting ischemia may be via ECG alone or with an added imaging modality. Notably, many patients with AMI who are managed conservatively initially may cross over to undergo invasive coronary angiography, without undergoing a noninvasive stress test. Common clinical indications for resorting to coronary angiography during the same AMI hospitalization after an initial conservative management trial include, but are not limited to: spontaneous non-inducible ischemia among patients already treated with aggressive medical therapies; LVSD, where a high level of suspicion for left main or multi-vessel coronary artery disease exists. These aforementioned scenarios are to be differentiated (and excluded from the denominator) from those during which coronary angiography is performed in initially conservatively managed AMI patients because of a high-risk noninvasive stress test.
Clinical Recommendation(s)
2013 ACCF/AHA Guideline for the Management of Patients With ST-Elevation Myocardial Infarction (12) 1. Noninvasive testing for ischemia should be performed before discharge to assess the presence and extent of inducible ischemia in patients with STEMI who have not had coronary angiography and do not have high-risk clinical features for which coronary angiography would be warranted (138, 140, 141 
Rationale
Troponins are components of the myocardial cell contractile apparatus. When measured in the circulation, they are very sensitive and specific to diagnose myocardial necrosis. In the correct clinical setting (e.g., angina/ischemic symptoms, ischemic changes on the ECG, imaging evidence of ischemia), a pattern of rise and fall in troponin I or T levels is essential to the diagnosis of AMI. Although STEMI is usually readily diagnosed by the presence of acute current of injury on the presenting ECG, patients with NSTE-ACS can present with nonspecific changes on the ECG (e.g., subtle or nonspecific ST or T wave changes). Thus, measuring troponin levels expeditiously help in the early diagnosis and risk stratification of these patients, which can lead to earlier triage and institution of appropriate medical and interventional treatments (11).
Clinical Recommendation(s)
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes (11) 1. Serial cardiac troponin I or T levels (when a contemporary assay is used) should be obtained at presentation and 3 to 6 hours after symptom onset in all patients who present with symptoms consistent with ACS to identify a rising and/or falling pattern of values (8, (142) (143) (144) (145) (146) (147) . (Class I, Level of Evidence: A) 2. Additional troponin levels should be obtained beyond 6 hours after symptom onset in patients with normal troponin levels on serial examination when changes on ECG and/or clinical presentation confer an intermediate or high index of suspicion for ACS (8, (148) (149) (150) . (Class I, Level of Evidence: A) 3. If the time of symptom onset is ambiguous, the time of presentation should be considered the time of onset for assessing troponin values (143, 145, 150 
Rationale
Therapeutic hypothermia in comatose patients with acute MI after certain types of cardiac arrest (predominantly related to VF or pulseless VT) has been shown to improve outcomes (e.g., increased survival to hospital discharge with good neurologic function, higher rate of a favorable neurologic outcome, and possibly reduced intermediate-term mortality) (12, (192) (193) (194) .
Clinical Recommendation(s)
2013 ACCF/AHA Guideline for the Management of Patients With ST-Elevation Myocardial Infarction (12) 1. Therapeutic hypothermia should be started as soon as possible in comatose patients with STEMI and out-of-hospital cardiac arrest caused by ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT), including patients who undergo primary 
